

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILINĠ DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/553,303	10/14/2005	Petra Cirpus	12810-00153-US	2158	
23416 CONNOLLY I	23416 7590 06/12/2007 CONNOLLY BOVE LODGE & HUTZ, LLP			. EXAMINER	
P O BOX 2207 WILMINGTON, DE 19899			BAGGOT, BRENDAN O		
WILMINGTO	N, DE 19899		ART UNIT PAPER NUMBER		
			1638		
			MAIL DATE	DELIVERY MODE	
			06/12/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
		10/553,303	CIRPUS ET AL.			
Office Action Summary		Examiner	Art Unit			
		Brendan O. Baggot	1638			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE in the may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION B6(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
,	Responsive to communication(s) filed on					
. —	This action is FINAL . 2b)⊠ This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	03 U.G. 213.			
Dispositi	on of Claims		·			
5) 6) 7)	Claim(s) 1-9,11 and 12 is/are pending in the ap 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-9, 11,12 are subject to restriction and	vn from consideration.				
Applicati	on Papers		,			
10)	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the lideral or b) objected to by the lideral or by the li	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority u	under 35 U.S.C. § 119	·				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) Notice 3) Information	ct(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) cmation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) cer No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Application/Control Number: 10/553,303

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I-III, claim(s) 1-9 and 12 drawn to a method of increasing total oil in a plant using a polynucleotide.

Group IV-VI, claim(s) 11, drawn to a method of extraction of oil from a transgenic plant produced by the method of I-III.

In addition to an election of one of inventions I-VI listed above, Applicant is required to elect one and only one of the following inventions to which the claims must be restricted.

Groups 1, 4: SEQ ID NO: 1 encoding SEQ ID NO: 2. Groups 2, 5: SEQ ID NO: 3 encoding SEQ ID NO: 4. Groups 3, 6: SEQ ID NO: 5 encoding SEQ ID NO: 6.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions are linked by the technical feature of a genetically modified plant. However, this technical feature is not special because it does not constitute an advance over the prior art. Hiatt, et al (US 4,801,540, 1989) teaches a genetically modified plant (see, e.g., claims 14, 1-13).

Furthermore, the invention of Group I-III, a first product, first method of making, and a first method of using, requires methods of plant transformation, DNA purification, cloning and etc, each not required by any Group IV-VI.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicants are reminded that nucleotide sequences encoding different proteins or comprising different regulatory sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121.

Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Applicant is required to select a single nucleotide sequence. This requirement is not to be construed as a requirement for an election of species, since each nucleotide sequence is not a member of single genus of invention, but constitutes an independent and patentably distinct invention.

Art Unit: 1638

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brendan O. Baggot whose telephone number is 571/272-5265. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571/272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Frendan O. Baggot Patent Examiner

Art Unit 1638

David H. Kruse, PhD Primary Examiner

Art Unit 1638

DAVID H. KRUSE, PH.D. PRIMARY EXAMINER

bob